The Association between Allergic Diseases and Migraine: A Systematic Review and Meta-Analysis
Abstract
Abstract Introduction: This study aimed to systematically review and summarize epidemiological evidence on the relationship between allergic diseases and migraine outcomes. Methods: This meta-analysis, which was registered with PROSPERO (CRD420250656492), employed data from PubMed, Embase, the Cochrane Library, and references from the studies included in the review. The search encompassed literature from the inception of these databases through February 24, 2025. We included observational studies investigating the association between allergic diseases and migraine. The risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS). Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using a random-effects model. Results: A total of 10 studies encompassing 14,952,953 participants were included. The overall risk for migraine in patients with allergic diseases was 1.52 (95% CI: 1.40–1.65). Specifically, the meta-analysis revealed an OR for atopic dermatitis of 1.27 (1.17–1.38), 1.49 (95% CI 1.32–1.68) for asthma, 2.16 (95% CI 1.43–3.24) for allergic rhinitis, and 1.74 (95% CI 1.43–2.10) for allergic conjunctivitis. Conclusion: The current meta-analysis suggests that allergic diseases are associated with an increased risk of developing migraines. However, further large-scale prospective cohort studies are required to validate the proposed association, considering the considerable heterogeneity observed in our analyses.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 14,952,953 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.